Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPA: Sevoflurane for ARDS Prevention
NCT05849779Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sevoflurane in acute respiratory distress syndrome (ARDS), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Started Jul 2023; status: recruiting.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05849779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849779.